Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase II |
| Species: | Human |
| Stage: | Primary analysis complete |
| Study Start Date: | 2005-02-03 |
| Study Made Public: | NA |
Title
A multicenter, double-blind, randomized, placebo-controlled Phase II proof-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in adults at high risk of HIV-1 infection
Description
HVTN 502 (STEP study/Merck V520-023) is a Phase II clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag/pol/nef (Ad5).
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.